First Rheumatoid Arthritis Patient Dosed in Phase Ⅲ Clinical Study of LNK01001
BOSTON and HANGZHOU and SHANGHAI, China, Dec. 20, 2023. Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as ' Lynk Pharmaceuticals ' ), an innovative clinical stage company, announced that it has dosed the first patient with Rheumatoid Arthritis...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Arthritis | China Health | Clinical Trials | Pharmaceuticals | Rheumatoid Arthritis | Rheumatology | Study